Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of General Virology

• Publication date

  1994-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1099/0022-1317-75-2-341PMID 7509370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetics of Retroviruses a

  1995cited by this paper
• Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates

  1993cited by this paper
• Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains.

  1993cited by this paper
• HIV‐1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment

  1992cited by this paper
• Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera

  1992cited by this paper
• 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

  1992cited by this paper
• Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

  1992cited by this paper
• HIV‐1 biological phenotype in long‐term infected individuals evaluated with an MT‐2 cocultivation assay

  1992cited by this paper
• Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

  1992cited by this paper
• Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

  1992cited by this paper
• Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.

  1992influential reference
• Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

  1991cited by this paper
• Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture

  1991cited by this paper
• Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis

  1991cited by this paper
• Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro

  1991cited by this paper
• HIV-1 env sequence variation in brain tissue of patients with AIDS-related neurologic disease.

  1991cited by this paper
• Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors

  1991cited by this paper
• Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

  1991cited by this paper
• Independent fluctuation of human immunodeficiency virus type 1 rev and gp41 quasispecies in vivo

  1991cited by this paper
• Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.

  1991cited by this paper
• Reversion from zidovudine resistance to sensitivity on cessation of treatment.

  1991cited by this paper
• Modified protocol for DNA sequence analysis using Sequenase 2.0.

  1991cited by this paper
• Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

  1991cited by this paper
• Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus.

  1991cited by this paper
• Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay

  1990cited by this paper
• DNA recombination during PCR.

  1990cited by this paper
• Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells

  1990cited by this paper
• Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination.

  1990cited by this paper
• Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.

  1990cited by this paper
• Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.

  1990cited by this paper
• Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.

  1990cited by this paper
• Isolation of drug‐resistant variants of HIV‐1 from patients on long‐term zidovudine therapy

  1989cited by this paper
• HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

  1989cited by this paper
• HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions.

  1989cited by this paper
• Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations.

  1989cited by this paper
• Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.

  1989cited by this paper
• Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

  1989cited by this paper
• Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity

  1988cited by this paper
• Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

  1985cited by this paper
• Oligonucleotide-Directed Mutagenesis: A Simple Method Using Two Oligonucleotide Primers and a Single-Stranded DNA Template

  1984cited by this paper
• Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes.

  1983influential reference
• 7 Genetics of Retroviruses

  1982cited by this paper
• Genetic recombination between avian leukosis and sarcoma viruses. Experimental variables and the frequencies of recombination.

  1977cited by this paper
• DNA sequencing with chain-terminating inhibitors.

  1977cited by this paper
• Evidence for crossing-over between avian tumor viruses based on analysis of viral RNAs.

  1974cited by this paper

• The clarifying role of time series data in the population genetics of HIV

  2018cites this paper
• Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries

  2017cites this paper
• Dynamic Convergent Evolution Drives the Passage Adaptation across 48 Years' History of H3N2 Influenza Evolution.

  2016cites this paper
• Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.

  2016cites this paper
• Evaluating the within-host fitness effects of mutations fixed during virus adaptation to different ecotypes of a new host

  2015cites this paper
• Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase

  2015influential citation
• 70th Anniversary Collection of the Microbiology Society: Journal of General Virology.

  2015cites this paper
• Commentary 70 th Anniversary Collection of the Microbiology Society : Journal of General Virology

  2015cites this paper
• First Report on a T69-ins Insertion in CRF06_cpx HIV Type 1

  2013cites this paper
• The genetic causes of convergent evolution

  2013cites this paper
• Trends in Prevalence of HIV‐1 Drug Resistance in Thailand 2009–2010

  2013cites this paper
• Pharmacotherapy of human immunodeficiency virus infection

  2013cites this paper
• Replaying the Tape of Life: Quantification of the Predictability of Evolution

  2012cites this paper
• The investigation of genotypic antiretroviral drug resistance in the context of the South African national antiretroviral roll-out programme

  2012cites this paper
• Statistical genetics and evolution of quantitative traits

  2011cites this paper
• Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1.

  2010cites this paper
• Novel Mechanisms of Resistance to HIV-1 Reverse Transcriptase (RT) Inhibitors: A Molecular and Clinical Characterization of Mutations in the Connection and RNase H Domains of RT

  2010cites this paper
• The Evolution and Emergence of RNA Viruses

  2009cites this paper
• Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase

  2008cites this paper
• AZT-resistant foamy virus.

  2008cites this paper
• Antiretroviral (ARV) drug resistance in the developing world.

  2007cites this paper
• N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance

  2007cites this paper
• Estudio de carcterísticas fenotípicas del VIH mediante la generación y desarrollo de virus recombinantes: aplicación al estudio de la capacidad replicativa de virus multirresistentes

  2007cites this paper
• Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level.

  2006cites this paper
• ANTAGONISTIC EVOLUTIONARY PATHWAYS OF HIV-1 RESISTANCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS: A VIROLOGICAL, BIOCHEMICAL AND CLINICAL INVESTIGATION

  2005cites this paper
• Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility.

  2004cites this paper
• Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors

  2004cites this paper
• Study of Antiretroviral Drug–Resistant HIV-1 Genotypes in Northern Thailand: Role of Mutagenically Separated Polymerase Chain Reaction as a Tool for Monitoring Zidovudine-Resistant HIV-1 in Resource-Limited Settings

  2004cites this paper
• Predictive Factors and Selection of Thymidine Analogue Mutations by Nucleoside Reverse Transcriptase Inhibitors According to Initial Regimen Received

  2003cites this paper
• Crystal Structures of Zidovudine- or Lamivudine-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptases Containing Mutations at Codons 41, 184, and 215

  2002cites this paper
• HIV RESISTANCE TO ANTIRETROVIRAL DRUGS: MECHANISMS, GENOTYPIC AND PHENOTYPIC RESISTANCE TESTING IN CLINICAL PRACTICE

  2002cites this paper
• HIV-1 Fitness : Implications for Drug Resistance , Disease Progression , and Global Epidemic Evolution

  2002cites this paper
• Effects of Specific Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeficiency Virus Type 1 Reverse Transcriptase

  2002influential citation
• Molecular basis of adaptive convergence in experimental populations of RNA viruses.

  2002cites this paper
• Mutagenically Separated PCR Assay for Rapid Detection of M41L and K70R Zidovudine Resistance Mutations in CRF01_AE (Subtype E) Human Immunodeficiency Virus Type 1

  2002cites this paper
• Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV‐1 in relation to treatment with nucleoside analogue RT inhibitors

  2002cites this paper
• Effects of Specific Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeficiency Virus Type 1 Reverse Transcriptase

  2002influential citation
• Resistance and cross‐resistance to abacavir

  2001cites this paper
• Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.

  2001cites this paper
• Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses

  2001cites this paper
• Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing.

  2001cites this paper
• Big-benefit mutations in a bacteriophage inhibited with heat.

  2000cites this paper
• Resistance against reverse transcriptase inhibitors.

  2000cites this paper
• Les multiples aspects de la résistance du VIH aux antirétroviraux

  2000cites this paper
• Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy

  2000cites this paper
• Considerations in the Management of HIV Infection in Patients Undergoing Antineoplastic Chemotherapy

  2000cites this paper
• Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.

  2000cites this paper
• A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1

  2000cites this paper
• Relative Replication Fitness of a High-Level 3′-Azido-3′-Deoxythymidine-Resistant Variant of Human Immunodeficiency Virus Type 1 Possessing an Amino Acid Deletion at Codon 67 and a Novel Substitution (Thr→Gly) at Codon 69

  2000cites this paper
• Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

  1999cites this paper
• Managing Resistance to Anti-HIV Drugs

  1999cites this paper
• Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.

  1999cites this paper
• Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations.

  1999cites this paper
• Different trajectories of parallel evolution during viral adaptation.

  1999cites this paper
• The rationale for a study on HIV-1 reverse transcriptase mutations and outcome of antiretroviral therapy with two nucleoside analogs.

  1999cites this paper
• Virus and host determinants of HIV-1 infection and AIDS pathogenesis

  1999cites this paper
• Associations between Amino Acids in the Evolution of HIV Type 1 Protease Sequences under Indinavir Therapy

  1999cites this paper
• A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance

  1999cites this paper
• Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy.

  1999cites this paper
• Active HIV-1 redistribution and replication in the brain with HIV encephalitis

  1999cites this paper
• A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine

  1998cites this paper
• Saquinavir delays the emergence of zidovudine resistance in HIV‐1 seropositive patients treated with combination therapy

  1998cites this paper
• 3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.

  1998cites this paper
• Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy

  1998cites this paper
• Overview on HIV-1-related drug resistance: from theory to clinical practice.

  1998cites this paper
• Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.

  1998cites this paper
• Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro

  1998cites this paper
• Antiretroviral Therapy for HIV Infection

  1998cites this paper
• Development of Lys to Arg Mutation at Codon 70 of the Reverse Transcriptase Gene of HIV-1 during Zidovudine Monotherapy and Alternating Zidovudine/Didanosine Therapy

  1998influential citation
• Difference of virus populations in HIV carriers in relation to AZT treatment.

  1997cites this paper
• Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors.

  1997cites this paper
• Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions.

  1997cites this paper
• Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice.

  1997cites this paper
• Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.

  1997cites this paper
• Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population.

  1997cites this paper
• Adaptation to the fitness costs of antibiotic resistance in Escherichia coli

  1997cites this paper
• Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine

  1996cites this paper
• Development of zidovudine-resistant HIV genotypes following postnatal prophylaxis in a perinatally infected infant.

  1996cites this paper
• Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet

  1996cites this paper
• An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine

  1996influential citation
• Reverse transcriptase mutations in HIV-1-infected children treated with zidovudine.

  1996cites this paper
• Development of resistance to zidovudine (ZDV) and didanosine (ddl) in HIV from patients in ZDV, ddl and alternating ZDV/ddl therapy

  1996cites this paper
• Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients.

  1996cites this paper
• Site-directed mutagenic analysis of viral polymerases and related proteins.

  1996cites this paper
• Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group

  1996cites this paper
• Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.

  1996cites this paper
• Molecular biology and evolution of resistance of toxicants.

  1996cites this paper
• Effect of isoprinosine on 3'-Azido-3'-deoxythymidine uptake and phosphorylation in human peripheral blood mononuclear cells.

  1996cites this paper
• Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility

  1996cites this paper
• Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: Longitudinal evaluation of six patients under treatment

  1996influential citation
• Independent evolution of the env and pol genes of HIV‐1 during zidovudine therapy

  1996cites this paper
• Use of Viral Resistance Patterns to Antiretroviral Drugs in Optimising Selection of Drug Combinations and Sequences

  1996cites this paper
• Studies of zidovudine in combination with didanosine and zalcitabine.

  1995cites this paper
• Antiviral therapy for human immunodeficiency virus infections

  1995cites this paper
• Distinct HIV‐1 long terminal repeat quasispecies present in nervous tissues compared to that in lung, blood and lymphoid tissues of an AIDS patient

  1995cites this paper
• Viral resistance and the selection of antiretroviral combinations.

  1995cites this paper
• Inhibition by azidothymidine triphosphate of reverse transcriptase from paired AZT-susceptible and -resistant primary isolates of human immunodeficiency virus type 1

  1995cites this paper
• Reverse transcriptase mutations in sequential HIV‐1 isolates in a patient with AIDS

  1995cites this paper
• Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC.

  1995cites this paper
• HIV Variation: Consequences for antiviral therapy and disease progression

  1995cites this paper